Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Gillian Mitchell et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Carol Aghajanian et al.|Gynecologic Oncology|2015Cited by 300